Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H22O10 |
| Molecular Weight | 482.4362 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(O)C=CC(=C1)[C@@H]2OC3=CC=C(C=C3O[C@H]2CO)[C@H]4OC5=CC(O)=CC(O)=C5C(=O)[C@@H]4O
InChI
InChIKey=FDQAOULAVFHKBX-WAABAYLZSA-N
InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-18-7-12(3-5-16(18)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23-,24-,25+/m0/s1
| Molecular Formula | C25H22O10 |
| Molecular Weight | 482.4362 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Milk thistle (Silybum marianum) has been used for centuries for the treatment of liver disorders and as a hepatoprotectant. The primary extract of milk thistle is termed silymarin, a complex mixture that contains a number of structurally-related flavonolignans, the flavonoid, taxifolin, and a number of other constituents. The major flavonolignans present in most extracts are silybin A, silybin B, isosilybin A and isosilybin B, silydianin, silychristin and isosilychristin. Isosilybin B elicited the strongest anti-NF-kappaB and anti-HCV actions. The data suggest that silymarin-derived compounds may influence HCV disease course in some patients. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3721 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28457856 |
|||
Target ID: CHEMBL2364675 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23801821 |
60.0 µM [IC50] | ||
Target ID: GO:0001525 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22514647 |
|||
Target ID: CHEMBL3397 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19934397 |
74.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. | 2013-09 |
|
| Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling. | 2012 |
|
| Identification of hepatoprotective flavonolignans from silymarin. | 2010-03-30 |
|
| Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. | 2010-03 |
|
| Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. | 2008-06-26 |
|
| Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. | 2007-05 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22514647
Mice: 50 and 100 mg/kg body weight
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18332867
Isosilybin B (10-90 uM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:56:00 GMT 2025
by
admin
on
Mon Mar 31 21:56:00 GMT 2025
|
| Record UNII |
15EH97604R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
1488 (Number of products:2)
Created by
admin on Mon Mar 31 21:56:00 GMT 2025 , Edited by admin on Mon Mar 31 21:56:00 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID80447055
Created by
admin on Mon Mar 31 21:56:00 GMT 2025 , Edited by admin on Mon Mar 31 21:56:00 GMT 2025
|
PRIMARY | |||
|
10885340
Created by
admin on Mon Mar 31 21:56:00 GMT 2025 , Edited by admin on Mon Mar 31 21:56:00 GMT 2025
|
PRIMARY | |||
|
15EH97604R
Created by
admin on Mon Mar 31 21:56:00 GMT 2025 , Edited by admin on Mon Mar 31 21:56:00 GMT 2025
|
PRIMARY | |||
|
m9941
Created by
admin on Mon Mar 31 21:56:00 GMT 2025 , Edited by admin on Mon Mar 31 21:56:00 GMT 2025
|
PRIMARY | Merck Index | ||
|
142796-22-3
Created by
admin on Mon Mar 31 21:56:00 GMT 2025 , Edited by admin on Mon Mar 31 21:56:00 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |